2016 Volume 18 Issue 1 Pages 5-9
Fondaparinux s.c. has been used instead of unfractionated heparin div. as a first line treatment for pulmonary thromboembolism (PTE) and deep vein thrombosis (DVT) in our clinical pathway since March 1, 2011. We retrospectively recruited 47 patients (heparin group: 27 pts, fondaparinux group: 20 pts) who had been treated with PTE and/or DVT between January 1, 2008, and June 30, 2014. Various parameters were used to compare the two groups, such as length of stay (LOS), mortality, readmission and complication rate. LOS was significantly shorter in the fondaparinux group than in heparin group (16.33 ± 6.45 days vs. 21.08 ± 5.93 days, p=0.018). No significant differences in mortality, readmission or complication rate were found between the two groups. No bleeding complications occurred in fondaparinux group. Fondaparinux s.c. is a feasible, safe treatment for PTE and DVT when compared with unfractionated heparin div. in terms of LOS.
